This post is
the second in a series on increasing adolescent immunizations. For a case study
on how one health system increased their overall adolescent vaccination rates,
see our previous post.
The CPP 2nd Dose Program provides an opportunity to examine your practice’s 2nd dose immunization rates for vaccines that require more than one dose to complete the series, access resources to help implement a strategy in your office to raise those rates, and share successful strategies with other CPP members. Applicable vaccines include meningococcal ACWY, HPV, adult pneumococcal and/or adult hepatitis B (Heplisav-B only).
The tables below show immunization rates for these vaccines for the most recent year available from the CDC:
in CPP’s 2nd Dose Program have already seen successes. Over 77%
of member participants reported that their 2nd dose immunization rates were
lower than they expected when they pulled the initial data from their
EMR. After implementing an intervention in their practice to help improve
these rates, participants saw a rise in their HPV and MCV4 completion rates by an
average of 29% and 41%, respectively!
best practices that were shared by the group include:
This post is the first
in a series on adolescent vaccination.
When Sanford Health, a rural not-for-profit health system
based in the Dakotas, Minnesota, and Iowa, took
a look at their adolescent vaccination rates, they were shocked by what
they found. Baseline rates for the completion of the HPV series ranged from 15%-29%
in their clinics, and rates for completion of the Meningococcal series ranged
from just 8%-38%. Sanford decided to make system-wide changes to improve their
adolescent vaccination rates.
Sanford began by creating an immunization strategy department
lead by the Immunization Strategy Manager. A cross-department team gathered to
form an enterprise immunization committee and craft a plan. The initial stage
focused on increasing administration of the HPV vaccine at a test group of
seven clinics. The strategy consisted of three parts:
Providers were given their immunization rates as
well as those of their colleagues. This put accurate data into the providers’
hands and engendered a sense of competition between staff.
Sanford emphasized a “no missed vaccination
opportunity” culture, encouraging providers to assess immunization status for
every patient at every encounter.
The system sent reminder and recall letters to
parents of adolescents.
Over the two year test period, HPV completion rates
increased by an average of 15%, and zero-dose rates decreased an average of
22%. Armed with this data, Sanford made plans to expand the program. The
organization added standing orders for most vaccines, enabling RNs, LPNs, and
MAs to administer immunizations. These orders eliminated more missed
opportunities and empowered staff to own their immunization rates.
Sanford, with the help of the Immunization Action Coalition
and Sanofi Pasteur, also created a curriculum to train people to become
immunization champions. The VAX Champ program created immunization champions
content experts for each clinic. The program also trained its students to
examine current vaccination rates and create plans to improve them. These
interventions saw first and second dose rates for MenACWY climb steadily. In
some clinics, second dose rates more than doubled.
Sanford Health’s efforts helped to not only increase
adolescent vaccination rates but also advanced their mission to improve patient
health. These steps can be applied to healthcare systems or offices of any
size. Sanford’s success shows that with dedication and a solid plan adolescent
immunization rates can improve.
Next in this series is a guide to CPP’s 2nd Dose
Program that rewards members for improving second dose rates of several
immunizations, including those that Sanford highlighted. For more information,
visit our website.
Recently, Sanofi Pasteur provided an update for the distribution of influenza vaccine for the 2019-2020 flu season. Due to late-emerging A/H3N2 viruses that delayed the strain selection for the upcoming flu season, it is anticipated that the delivery of Sanofi Pasteur influenza vaccines will be approximately 3-4 weeks behind the shipping commitments previously communicated. Sanofi Pasteur fully expects to manufacture and deliver every dose reserved by their customers, beginning with partial shipments to all customers in late-August or September, with all shipments completed by the end of November.
Each year, the World Health Organization (WHO) and U.S. Food
and Drug Administration (FDA), with help from epidemiologists around the world,
select the virus strains to be included in influenza vaccines for the upcoming
season. This year, due to late-emerging A/H3N2 viruses that circulated
globally, the WHO and FDA decided to delay selection of the A/H3N2 strain by
one month. This allowed health authorities to collect additional data to
help improve the match of the vaccine strain to the A/H3N2 strain anticipated
to circulate during the 2019-2020 season.
Sanofi Pasteur fully supports
this decision by health authorities to collect additional data and make a more
If you have any questions, please feel free to contact the CPP office at 614-722-2145 or your Sanofi Pasteur representative.